Compile Data Set for Download or QSAR
Report error Found 65 Enz. Inhib. hit(s) with Target = 'E3 ubiquitin-protein ligase SMURF1 [420-757]'
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239101(US9403810, 2.2 | US10195181, Example 2.2)
Affinity DataIC50: 0.900nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239132(US9403810, 22c)
Affinity DataIC50: 1.40nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239094(US9403810, 1.3 | US10195181, Example 1.3)
Affinity DataIC50: 1.80nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239092(US9403810, 1.1 | US10195181, Example 1.1)
Affinity DataIC50: 2.10nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239099(US9403810, 2 | US10195181, Example 2)
Affinity DataIC50: 2.5nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239091(US9403810, 1 | US10195181, Example 1)
Affinity DataIC50: 2.80nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239095(US9403810, 1.4 | US10195181, Example 1.4)
Affinity DataIC50: 3.20nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239105(US9403810, 6 | US10195181, Example 6)
Affinity DataIC50: 5.70nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239102(US9403810, 3 | US10195181, Example 3)
Affinity DataIC50: 6nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239096(US9403810, 1.5 | US10195181, Example 1.5)
Affinity DataIC50: 6nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239097(US9403810, 1.6 | US10195181, Example 1.6)
Affinity DataIC50: 8nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239093(US9403810, 1.2 | US10195181, Example 1.2)
Affinity DataIC50: 14nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239107(US9403810, 7 | US10195181, Example 7)
Affinity DataIC50: 19nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239106(US9403810, 6.1 | US10195181, Example 6.1)
Affinity DataIC50: 23nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239098(US9403810, 1.7 | US10195181, Example 1.7)
Affinity DataIC50: 33nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239126(US9403810, 16)
Affinity DataIC50: 37nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239108(US9403810, 8 | US10195181, Example 8)
Affinity DataIC50: 46nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239110(US9403810, 10 | US10195181, Example 10)
Affinity DataIC50: 50nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238981(US9403833, 16)
Affinity DataIC50: 55nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239109(US9403810, 9 | US10195181, Example 9)
Affinity DataIC50: 58nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239100(US9403810, 2.1 | US10195181, Example 2.1)
Affinity DataIC50: 64nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239120(US9403810, 25d)
Affinity DataIC50: 74nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239137(US9403810, 25b)
Affinity DataIC50: 75nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239128(US9403810, 18)
Affinity DataIC50: 91nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238975(US9403833, 12 | US9403833, 10)
Affinity DataIC50: 92nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238975(US9403833, 12 | US9403833, 10)
Affinity DataIC50: 98nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239103(US9403810, 4 | US10195181, Example 4)
Affinity DataIC50: 100nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239122(US9403810, 12 | US10195181, Example 12)
Affinity DataIC50: 100nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239133(US9403810, 23)
Affinity DataIC50: 160nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239119(US9403810, 25a)
Affinity DataIC50: 160nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239115(US9403810, 20 | US10195181, Example 20)
Affinity DataIC50: 180nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238979(US9403833, 14)
Affinity DataIC50: 230nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239136(US9403810, 24b)
Affinity DataIC50: 250nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239123(US9403810, 13a)
Affinity DataIC50: 290nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239124(US9403810, 15a)
Affinity DataIC50: 290nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239104(US9403810, 5 | US10195181, Example 5)
Affinity DataIC50: 310nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239134(US9403810, 24)
Affinity DataIC50: 340nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239135(US9403810, 24a | US10195181, Example 24b)
Affinity DataIC50: 350nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239111(US9403810, 11 | US10195181, Example 11)
Affinity DataIC50: 420nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239118(US9403810, 22a)
Affinity DataIC50: 420nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238966(US9403833, 1)
Affinity DataIC50: 440nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239130(US9403810, 21.2 | US10195181, Example 21.2)
Affinity DataIC50: 490nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238970(US9403833, 5)
Affinity DataIC50: 550nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239117(US9403810, 22 | US10195181, Example 22c)
Affinity DataIC50: 570nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM238967(US9403833, 2)
Affinity DataIC50: 570nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239121(US9403810, 26 | US10195181, Example 26)
Affinity DataIC50: 580nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239125(US9403810, 15b)
Affinity DataIC50: 630nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239116(US9403810, 21.1 | US10195181, Example 21.1)
Affinity DataIC50: 630nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239112(US9403810, 13)
Affinity DataIC50: 640nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Human)
Novartis

US Patent
LigandPNGBDBM239113(US9403810, 13b | US10195181, Example 13a)
Affinity DataIC50: 730nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 65 total ) | Next | Last >>
Jump to: